Shanghai Allist Pharmaceuticals Co. Ltd. has synthesized nitrogen-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) and (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Genetically modified derivatives of the chimeric oncolytic virus (OV) CF33 have previously shown cancer selectivity and oncolytic potency against various solid tumors.
Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical (Shanghai) Ltd. have synthesized antibody-drug conjugates consisting of an antibody covalently linked to exatecan derivatives through a linker.
Astellas Pharma Inc. reported top-line results showing zolbetuximab, a monoclonal antibody targeting Claudin 18.2, met the primary endpoint for progression-free survival as well as secondary endpoints for overall survival in the phase III Glow trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Astellas Pharma Inc. reported top-line results showing zolbetuximab, a monoclonal antibody targeting Claudin 18.2, met the primary endpoint for progression-free survival (PFS) as well as secondary endpoints for overall survival (OS) in the phase III Glow trial in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Blossomhill Therapeutics Inc. has identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
The high and specific expression of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) in multiple types of tumors makes it an ideal target for drug delivery.
Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have identified heterocyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
